https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-carvykti-multiple-myeloma
FDA Approves Carvykti CAR T-Cell Therapy for Multiple Myeloma - NCI
FDA has approved ciltacabtagene autoleucel (Carvykti) for adults with multiple myeloma that is not responding to treatment or has returned after treatment.
car t cell therapymultiple myelomafdaapprovescarvykti
https://www.vidal.fr/medicaments/gammes/carvykti-109487.html
CARVYKTI
carvykti
https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-carvykti-multiple-myeloma?cid=eb_govdel
FDA Approves Carvykti CAR T-Cell Therapy for Multiple Myeloma - NCI
FDA has approved ciltacabtagene autoleucel (Carvykti) for adults with multiple myeloma that is not responding to treatment or has returned after treatment.
car t cell therapymultiple myelomafdaapprovescarvykti